Ionis Pharmaceuticals Surges Pre-Market on FDA Priority Review for Alexander Disease Drug
Ionis Pharmaceuticals Inc. (NASDAQ: IONS) is experiencing a notable surge in pre-market trading this Thursday, climbing +2.77% ahead of the open. The significant early move is primarily driven by the U.S. Food and Drug Administration's (FDA) acceptance of a New Drug Application (NDA) for zilganersen, an investigational treatment for Alexander disease, under Priority Review. This development highlights a crucial step forward for a condition with no approved disease-modifying therapies.
Shares of Ionis Pharmaceuticals are up +2.77% in early trading, significantly outperforming a flat S&P 500 (SPY: +0.00%). The biotechnology firm's positive momentum stems from a pivotal regulatory update concerning its pipeline. The FDA has granted Priority Review to Ionis's New Drug Application for zilganersen, an RNA-targeted medicine aimed at treating Alexander disease (AxD), a rare, progressive, and often fatal neurological disorder. The agency has set a Prescription Drug User Fee Act (PDUFA) target action date of September 22, 2026, signaling an expedited review process for this much-needed therapy.
Analyst Optimism Fuels Further Gains
The positive FDA news is compounded by recent bullish sentiment from Wall Street analysts. Today, Barclays raised its price target for IONS to $106 from $95, maintaining an "Overweight" rating on the stock. This follows similar upgrades from earlier in the week: HC Wainwright & Co. increased its price target from $110 to $120, while Needham adjusted its target from $103 to $105. Oppenheimer also raised its price target to $104 from $96, citing the strategic pricing adjustment for the company's drug Tryngolza and the zilganersen priority review as key factors. These revisions underscore growing confidence in Ionis's clinical pipeline and commercial prospects.
Broader Pipeline Progress
Beyond zilganersen, Ionis also recently announced that the FDA accepted a supplemental New Drug Application (sNDA) for olezarsen for severe hypertriglyceridemia (sHTG), also granting it Priority Review. The PDUFA date for olezarsen is set for June 30, 2026. These dual priority reviews for key investigational medicines highlight the company's robust development capabilities within the Biotechnology and Pharmaceuticals & Biotech sectors. The market appears to be reacting favorably to the potential for multiple new drug approvals in areas of high unmet medical need, positioning Ionis for continued attention from investors as these regulatory milestones approach.
Key Takeaways
- Ionis Pharmaceuticals (IONS) is up +2.77% in pre-market trading, driven by positive regulatory news.
- The FDA has granted Priority Review to zilganersen for Alexander disease, with a PDUFA date of September 22, 2026, addressing a significant unmet medical need.
- Multiple analysts, including Barclays, HC Wainwright, Needham, and Oppenheimer, have recently raised their price targets for IONS, reflecting increased confidence in the company's pipeline.
- The FDA also accepted olezarsen for severe hypertriglyceridemia for Priority Review, with a PDUFA date of June 30, 2026.
- Ionis operates in the Biotechnology and Pharmaceuticals & Biotech sectors, focusing on RNA-targeted therapies.